Hosted on MSN

Biogen/Eisai present new Alzheimer’s Disease clinical trial data at CTAD

Eisai (ESAIY) and Biogen (BIIB) “announced that the latest data confirming the pharmacological effect of lecanemab, an anti-Abeta protofibril antibody, on Abeta protofibrils in cerebrospinal fluid was ...
European Medical Journal

Lecanemab Linked to Plasma Biomarker Changes in Alzheimer’s Disease

Lecanemab was linked to multidirectional shifts in plasma biomarkers of Alzheimer's disease. See which markers normalised and ...

Alzheimer’s treatment is advancing rapidly — and there’s one thing all of us can do to help

Believe the hype about the latest Alzheimer’s breakthroughs.
BIOENGINEER

Virtual Review Board Brings New Alzheimer’s Drugs to Community Neurologists Safely

A Sutter Health virtual review board allowed general neurologists to safely prescribe and monitor amyloid-targeting Alzheimer ...

Will Leqembi Become the Savior of Dementia? — What Changes and What Doesn't with the Approval of Subcutaneous Injection

On September 16, 2026, a subcutaneous injection formulation of the Alzheimer's disease treatment 'Leqembi' (generic name: ...
Yahoo Finance

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Healio

Lecanemab slows progression of novel Alzheimer’s-related biomarker over 18 months

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Lecanemab led to a 44% reduction of biomarker ...
MedPage Today

Alzheimer's Lecanemab Treatment Up to 36 Months Supported by Extension Study

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early Alzheimer's disease, initial findings from the CLARITY AD ...
NPR

An Alzheimer's drug is on the way, but getting it may still be tough. Here's why

The first drug shown to slow down Alzheimer's disease is likely to receive full approval from the Food and Drug Administration by July 6. In theory, the move would make lecanemab (Leqembi) available ...
aafp.org

Lecanemab (Leqembi) for the Slowing of Alzheimer Disease

Lecanemab (Leqembi) is labeled for the treatment of Alzheimer disease in adults with mild cognitive impairment or who are in the mild dementia stage of Alzheimer disease (eg, have a Mini-Mental State ...
Yahoo Finance

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Morningstar%2c Inc.

Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile

Results from the open-label long-term extension study (OLE) following the core study of the lecanemab phase 3 Clarity AD study presented at AAIC in July, showed that the mean change from baseline in ...